Risk Factors Update Summary
- Net loss for fiscal year 2023 is projected to be $498 million, down from $518 million in 2021.
- Number of tests performed decreased from 23,990 to 17,377, resulting in a 27% decline.
- Accumulated deficit decreased by $20 million, from $518 million to $498 million.
- Failure to expand payer coverage for Ova1Plus and OvaWatch could significantly impact financial results.
- Authorized shares increased by 50 million to 200 million, potentially causing significant dilution.
- Failure to maintain Nasdaq listing requirements could lead to delisting, impacting stock liquidity.
- Material weaknesses in internal controls over financial reporting could affect accurate financial reporting.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=926617&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.